Anti-C5 antibodies having improved pharmacokinetics

US9663574B2 · kind B2 · utility

Assignee

• Alexion Pharmaceuticals, Inc. · US

Inventors

• Bruce A. Andrien, Jr. · Guilford, US
• Douglas L. Sheridan · Branford, US
• Paul P. Tamburini · Kensington, US
• Yi Wang · Woodbridge, US

Key dates

• Filing date: May 20, 2016
• Grant date: May 30, 2017
• Expiry date: May 20, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.